Name | Number of supported studies | Average coverage | |
---|---|---|---|
pericyte | 7 studies | 29% ± 12% | |
smooth muscle cell | 5 studies | 29% ± 4% | |
enteroendocrine cell | 3 studies | 23% ± 4% | |
fibroblast | 3 studies | 23% ± 2% | |
pancreatic A cell | 3 studies | 39% ± 15% |
Insufficient scRNA-seq data for expression of SSTR2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 96% | 2391.54 | 2548 / 2642 | 94% | 15.86 | 666 / 705 |
breast | 95% | 666.28 | 435 / 459 | 79% | 9.09 | 880 / 1118 |
adrenal gland | 93% | 749.73 | 240 / 258 | 69% | 15.92 | 158 / 230 |
kidney | 99% | 1196.43 | 88 / 89 | 61% | 3.68 | 550 / 901 |
thymus | 90% | 473.54 | 588 / 653 | 42% | 0.92 | 256 / 605 |
prostate | 91% | 586.47 | 224 / 245 | 26% | 0.42 | 129 / 502 |
stomach | 87% | 341.52 | 313 / 359 | 25% | 0.54 | 71 / 286 |
uterus | 67% | 282.26 | 114 / 170 | 33% | 2.01 | 150 / 459 |
spleen | 100% | 2396.26 | 240 / 241 | 0% | 0 | 0 / 0 |
adipose | 98% | 906.45 | 1176 / 1204 | 0% | 0 | 0 / 0 |
pancreas | 21% | 52.74 | 70 / 328 | 64% | 7.10 | 114 / 178 |
lymph node | 0% | 0 | 0 / 0 | 79% | 6.55 | 23 / 29 |
liver | 40% | 103.61 | 90 / 226 | 37% | 1.95 | 149 / 406 |
bladder | 57% | 185.29 | 12 / 21 | 18% | 0.67 | 90 / 504 |
esophagus | 42% | 135.27 | 605 / 1445 | 31% | 0.91 | 57 / 183 |
intestine | 54% | 160.45 | 520 / 966 | 15% | 0.41 | 78 / 527 |
lung | 30% | 102.41 | 176 / 578 | 32% | 1.47 | 370 / 1155 |
tonsil | 0% | 0 | 0 / 0 | 47% | 3.22 | 21 / 45 |
blood vessel | 41% | 190.65 | 548 / 1335 | 0% | 0 | 0 / 0 |
muscle | 36% | 105.20 | 292 / 803 | 0% | 0 | 0 / 0 |
skin | 16% | 49.72 | 291 / 1809 | 20% | 0.43 | 94 / 472 |
heart | 33% | 99.13 | 285 / 861 | 0% | 0 | 0 / 0 |
ovary | 13% | 66.48 | 23 / 180 | 13% | 0.31 | 58 / 430 |
peripheral blood | 18% | 225.01 | 171 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 10% | 0.17 | 8 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_0038170 | Biological process | somatostatin signaling pathway |
GO_0007218 | Biological process | neuropeptide signaling pathway |
GO_0007283 | Biological process | spermatogenesis |
GO_0030900 | Biological process | forebrain development |
GO_0071392 | Biological process | cellular response to estradiol stimulus |
GO_0042594 | Biological process | response to starvation |
GO_0007193 | Biological process | adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway |
GO_0007187 | Biological process | G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger |
GO_0021549 | Biological process | cerebellum development |
GO_0071385 | Biological process | cellular response to glucocorticoid stimulus |
GO_0030432 | Biological process | peristalsis |
GO_0005886 | Cellular component | plasma membrane |
GO_0043005 | Cellular component | neuron projection |
GO_0005829 | Cellular component | cytosol |
GO_0004994 | Molecular function | somatostatin receptor activity |
GO_0030165 | Molecular function | PDZ domain binding |
GO_0042923 | Molecular function | neuropeptide binding |
GO_0005515 | Molecular function | protein binding |
Gene name | SSTR2 |
Protein name | Somatostatin receptor type 2 (SS-2-R) (SS2-R) (SS2R) (SST2) (SRIF-1) |
Synonyms | |
Description | FUNCTION: Receptor for somatostatin-14 and -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. In addition it stimulates phosphotyrosine phosphatase and PLC via pertussis toxin insensitive as well as sensitive G proteins. Inhibits calcium entry by suppressing voltage-dependent calcium channels. Acts as the functionally dominant somatostatin receptor in pancreatic alpha- and beta-cells where it mediates the inhibitory effect of somatostatin-14 on hormone secretion. Inhibits cell growth through enhancement of MAPK1 and MAPK2 phosphorylation and subsequent up-regulation of CDKN1B. Stimulates neuronal migration and axon outgrowth and may participate in neuron development and maturation during brain development. Mediates negative regulation of insulin receptor signaling through PTPN6. Inactivates SSTR3 receptor function following heterodimerization. . |
Accessions | P30874 ENST00000357585.4 [P30874-1] |